Bavar­i­an Nordic fields 'over­whelm­ing' in­ter­est in mon­key­pox vac­cine

About a month af­ter the mon­key­pox out­break emerged in Eu­rope, Bavar­i­an Nordic says it’s see­ing “over­whelm­ing” in­ter­est in its small­pox vac­cine Jyn­neos, in­clud­ing a new con­tract with Cana­da worth $56 mil­lion.

“We are ob­vi­ous­ly still in di­a­logue with a num­ber of coun­tries from dif­fer­ent re­gions of the world and we are ex­pect­ing to sign more con­tracts,” CFO Hen­rik Ju­uel said dur­ing a Tues­day morn­ing call with in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER